"Unexpected liver toxicity derailed a phase I melanoma trial of concurrent treatment with the first two targeted agents approved for the disease, according to a brief communication from investigators." Charles Bankhead, Staff Writer, MedPage Today
The NEJM piece on this trial is here.
Takeaway: Two wrongs don't make a right. Don't expect two crappy drugs to make a dramatically better one when combined.